Microdose GLP-1 — Important Safety Information
Low-dose GLP-1 therapy. Same class warnings apply as compounded semaglutide and tirzepatide.
Compounded drugs are permitted to be prescribed under federal law, but are not FDA-approved and do not undergo FDA safety, effectiveness, or manufacturing review. Your EOS Health-affiliated provider may recommend this medication based on your individual medical evaluation.
Microdose GLP-1 may use either compounded semaglutide or compounded tirzepatide depending on your individual treatment plan. The same class warnings apply as the full-dose versions of these medications. Please review the section that applies to your prescribed treatment, and consult your EOS Health-affiliated provider with any questions.
Important Safety Information for Compounded Tirzepatide
Contraindications
Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It should not be used in patients with a history of severe gastrointestinal disease, including gastroparesis.
Warnings and Precautions
- Risk of Thyroid C-Cell Tumors: Cases of MTC have been reported with GLP-1 receptor agonists.
- Pancreatitis: Acute pancreatitis has been reported. Discontinue and seek medical attention if symptoms occur.
- Hypoglycemia when used with insulin or insulin secretagogues.
- Acute Kidney Injury: Monitor renal function.
- Hypersensitivity Reactions including anaphylaxis, angioedema, urticaria.
- Gastrointestinal Adverse Reactions: Nausea, vomiting, diarrhea, constipation.
Most common reactions: nausea, vomiting, diarrhea, abdominal pain, constipation.
Pregnancy: Should not be used. Caution in breastfeeding.
Important Safety Information for Compounded Semaglutide
Warning: Risk of Thyroid C-Cell Tumors
- Semaglutide caused thyroid tumors in mice and rats. Tell your provider about any neck lump or swelling, hoarseness, trouble swallowing, or shortness of breath.
- Do not use if you or family have ever had MTC or MEN 2.
Who should not use semaglutide?
- Personal or family history of MTC or MEN 2
- Known allergic reaction to semaglutide
What to tell your provider
Share all medications and your full medical history, especially: diabetes, thyroid cancer, pancreatitis, kidney disease, diabetic retinopathy, depression, suicidal thoughts.
Most serious side effects
If experiencing a medical emergency, call 911.
- Thyroid C-cell tumors
- Acute pancreatitis
- Acute gallbladder disease
- Low blood sugar (hypoglycemia)
- Acute kidney injury
- Serious allergic reactions
- Diabetic retinopathy complications
- Increased heart rate
- Suicidal behavior and ideation
- Never share needles or syringes
Most common side effects
- Nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness.
Pregnancy and breastfeeding
- Should not be used during pregnancy.
- Discontinue at least 2 months before a planned pregnancy.
You are encouraged to report negative side effects to FDA MedWatch: www.fda.gov/medwatch or 1-800-FDA-1088.
This information is not comprehensive. Please reach out to your EOS Health-affiliated provider with any questions or concerns.